Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy

Por Lorenzoni, Valentina, Baccetti, Fabio, Genovese, Stefano, Torre, Enrico, Turchetti, Giuseppe
Publicado no Clinicoecon Outcomes Res (2017)

Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes

Por Torre, Enrico, Bruno, Giacomo Matteo, Di Matteo, Sergio, Martinotti, Chiara, Oselin, Martina, Valentino, Maria Chiara, Parodi, Alessio, Bottaro, Luigi Carlo, Colombo, Giorgio Lorenzo
Publicado no Clinicoecon Outcomes Res (2018)